AAFMAA Wealth Management & Trust LLC Has $2.46 Million Holdings in Boston Scientific Co. (NYSE:BSX)

AAFMAA Wealth Management & Trust LLC trimmed its position in Boston Scientific Co. (NYSE:BSX) by 17.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 24,349 shares of the medical equipment provider’s stock after selling 5,289 shares during the period. Boston Scientific accounts for approximately 1.1% of AAFMAA Wealth Management & Trust LLC’s investment portfolio, making the stock its 19th biggest position. AAFMAA Wealth Management & Trust LLC’s holdings in Boston Scientific were worth $2,456,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Gateway Investment Advisers LLC raised its position in Boston Scientific by 0.6% in the first quarter. Gateway Investment Advisers LLC now owns 603,863 shares of the medical equipment provider’s stock valued at $60,918,000 after purchasing an additional 3,838 shares during the last quarter. Elk River Wealth Management LLC acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $202,000. Procyon Advisors LLC raised its holdings in Boston Scientific by 104.4% in the 1st quarter. Procyon Advisors LLC now owns 4,765 shares of the medical equipment provider’s stock valued at $481,000 after buying an additional 2,434 shares during the last quarter. Consilio Wealth Advisors LLC bought a new position in Boston Scientific in the 1st quarter valued at approximately $201,000. Finally, Generali Investments Management Co LLC boosted its position in Boston Scientific by 14.4% during the 1st quarter. Generali Investments Management Co LLC now owns 30,912 shares of the medical equipment provider’s stock worth $3,118,000 after buying an additional 3,886 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. The trade was a 9.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock valued at $42,406,693 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $102.04 on Friday. The stock has a market capitalization of $150.96 billion, a price-to-earnings ratio of 81.63, a PEG ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock’s 50 day moving average price is $100.49 and its two-hundred day moving average price is $98.37.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific’s revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.56 earnings per share. On average, equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on BSX shares. Needham & Company LLC restated a “buy” rating and issued a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Robert W. Baird increased their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Morgan Stanley raised their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, May 16th. Evercore ISI upped their price target on Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Finally, Barclays increased their price target on Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Twenty-one research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.